Bibliografia

Bibliografia essenziale

Trapianto di fegato
- Rubin R.H. Infection in the organ transplant recipient. In: Clinical approach to infection in the compromised host. Eds.: Rubin R.H. and Young L.S. Plenum Medical Book Co. New York and London. 1994:629-705.

- Brayman K.L., Sthephanian E., Matas A.J., et al. Analysis of infectious complications occurring after solid-organ transplantation. Arch. Surg. 1992, 127:38-48.

- Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993, 329:1842.

- Rubin R.H. Infectious disease problems. In: Transplantation of the liver. Ed.: Maddrey W.C., Elsevier, New York. 1988:279-308.

- Tolkoff-Rubin N.E., Rubin R.H. Infections in the organ transplant recipient. In: Organ transplantation and replacement. Ed.: Cerilli G.J., J.B. Lippincott, Philadelphia. 1988:445-461.

- Castaldo P., Stratta R.J., Wood R.P., et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch. Surg. 1991, 126:149-156.

- Rubin R.H., Tolkoff-Rubin N.E. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob. Agents Chemother. 1993, 37:619-624.

- Arnow P.M. Prevention of bacterial infection in the transplant recipient. Infectious Disease Clinics of North America 1995, 9:849-862.

- Arnow P.A., Furmaga K., Flaherty J.P., et al. Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplantation. Antimicrob. Agents Chemother. 1992, 36:2125-2130.

- Raakow W.R., Steffen R., Lefebre B., et al. Selective bowel decontamination effectively prevents gram-negative bacterial infections after liver transplantation. Transpl. Proc. 1990, 22:1356-1557.

- Collins L.A., Samore M.H., Roberts M.S., et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation J. Infect. Dis. 1994, 170:644-652.

- Smiley M.L., Wlodaver C.G., Grossman R.A., et al. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 1985, 40:157.

- Sayers M.H., Anderson K.C. Goodnough L.T., et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann. Intern. Med. 1992, 116:55-62.

- Metselaar H.J., Rothbarth P.H., Brouwer R.M.L., et al. Prevention of cytomegalovirus related death by passive immunization: a double-blind, placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 1989, 48:264-266.

- Pakkala S., Salmela K., Lautenschlager I., et al. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients. Transplantation Proc. 1992, 24:283-284

- Winston D.J., Wirin D., Shaked A., et al. Randomised comparison of Gancyclovir and high dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995, 346:69-74

- Duncan S.R., Grgruich W.F., Iacono A.T., et al. A comparison of gancyclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am. J. Resp. Crit. Care Med. 1994, 150:146

- Rubin R.H. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med. 1991, 324:1057-1059.

- Hibberd P.L., Tolkoff-Rubin N.E., Cosimi A.B., et al. Symptomatic cytomegalovirus disease in the cytomeglovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992, 53:68.

- Fishman J.A. Pneumocystis Carinii and parasitic infections in transplantation.In: Infectious disease clinics of North America. 1995, 9:1005-1044.
- Basgoz N., Preiksaitis J.K. Post-transplant lymphoproliferative disorder. Infectious disease Clinics of North America. 1995, 9:901-923.

Trapianto di midollo

- Meyers J.D.,Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986, 153 :478-488.

- Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD, Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992 80 :1358-1364.

- Einsele H, Ehninger G, Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86 :2815-2820.

- Goodrich JM, Mori M, Gleaves CA., et al. Prevention of cytomegalovirus disease after allogeneic marrow transplantation by early treatment with ganciclovir. N. Engl. J. Med. 1991, 325 :1601-1607.

- Schmidt GM, Horak DA, Niland JCC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic marrow transplants. N. Engl. J. Med. 1991, 324 :1005-1011.

- Bowden RA, Slichter SJ, Sayers M at al. A comparison of filtred leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated (CMV infection after marrow transplantation. Blood 1995, 86 :3598-3603.

- Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 1993, 118 :173-178.

- Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic boner marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. 1993, 118 : 179-184.

- Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phae I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. 1992, 166 :473-479.